ArticleCancer cell international2026
Sugen kinase 495 promotes the proliferation, migration and invasion of lung squamous cell carcinoma cells by targeting Foxo1 transcription factor.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Sugen kinase 495 (Sgk495), also known as Serine/Threonine Kinase 40 (STK40), is a pseudokinase previously implicated in T cell differentiation via regulation of Foxo transcription factors. However, its function and mechanism in lung squamous cell carcinoma (LUSC) remain unclear. Here, we report that Sgk495 is highly expressed in LUSC tissues and correlates with shorter disease-free survival in patients. Knockdown of Sgk495 significantly inhibited the proliferation, migration, and invasion of LUSC cells. Mechanistically, Sgk495 facilitates the binding of the E3 ubiquitin ligase COP1 to Foxo1, enhancing K48-linked polyubiquitination and subsequent proteasomal degradation of Foxo1. This process alleviates the tumor-suppressive effects of Foxo1, thereby promoting the oncogenic capabilities of LUSC cells in vivo. Our findings identify Sgk495 as an oncogene in LUSC acting through the COP1/Foxo1 axis, revealing a potential therapeutic target for this malignancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.